+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
TATVA

Tatva Chintan Pharma Chem Share Price

 
New 52W High in past week

 

Tatva Chintan Pharma Chem live price: ₹1,664.90. It opened at ₹1,700 vs previous close ₹1,685; intraday high/low: ₹1,720/₹1,632. The 50 & 200 DMA stand at ₹1,301.40/₹1,224.00.

Tatva Chintan Pharma Chem Performance

  • Today's Low
  • ₹1,632
  • Today's High
  • ₹1,720
  • 52 Week Low
  • ₹976
  • 52 Week High
  • ₹1,785
  • Open Price₹1,700
  • Previous Close₹1,685
  • Volume370,707
  • 50 DMA₹1,301.40
  • 100 DMA₹1,265.10
  • 200 DMA₹1,224.00

Tatva Chintan Pharma Chem Chart

Investment Returns

  • Over 1 Month + 39.44%
  • Over 3 Month + 30.15%
  • Over 6 Month + 20.05%
  • Over 1 Year + 61.48%

Smart Investing Starts Here Start SIP with Tatva Chintan Pharma Chem for Steady Growth!

Invest Now

Tatva Chintan Pharma Chem Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 75.8
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 3,895
  • P/B Ratio
  • 5
  • Average True Range
  • 78.1
  • EPS
  • 22
  • Dividend Yield
  • 0.1
  • MACD Signal
  • 108.7
  • RSI
  • 76.25
  • MFI
  • 92.44

Latest Stock News Updates

Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Transcript of the earnings call held on 17 July 2026 post announcement of the financial results of the Company for the quarter ended 30 June 2026.

Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Tatva Chintan Pharma Chem Financials

Tatva Chintan Pharma Chem Technicals

EMA & SMA

Current Price
₹1,664.90
-20.1 (-1.19%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹1,397.30
  • 50 Day
  • ₹1,301.40
  • 100 Day
  • ₹1,265.10
  • 200 Day
  • ₹1,224.00

Resistance and Support

1672.37 Pivot Speed
  • R3 1,800.30
  • R2 1,760.20
  • R1 1,712.50
  • S1 1,624.70
  • S2 1,584.60
  • S3 1,536.90

Tatva Chintan Pharma Chem Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-07-17 Quarterly Results
2026-05-16 Audited Results & Final Dividend
2026-01-21 Quarterly Results
2025-10-31 Quarterly Results
2025-07-24 Quarterly Results
Date Purpose Remarks
2025-09-12 FINAL Rs.1.00 per share(10%)Final Dividend
2022-09-09 FINAL Rs.2.00 per share(20%)Final Dividend
View Tatva Chintan Pharma Chem Dividend History Arrow

Tatva Chintan Pharma Chem Shareholding Pattern

72.02%
20.94%
3.93%
2.79%
0.32%

About Tatva Chintan Pharma Chem

Tatva Chintan Pharma Chem is primarily engaged in manufacturing, sale and distribution of specialty chemicals, viz., phase transfer catalysts (PTC), structure directing agents (SDA), electrolyte salts and solutions (ESS), pharmaceutical and agrochemical i View More
  • NSE Symbol
  • TATVA
  • BSE Symbol
  • 543321
  • ISIN
  • INE0GK401011

Similar Stocks to Tatva Chintan Pharma Chem

Tatva Chintan Pharma Chem FAQs

Tatva Chintan Pharma Chem share price is ₹1,664 As on 22 July, 2026 | 18:14

The Market Cap of Tatva Chintan Pharma Chem is ₹3894.6 Cr As on 22 July, 2026 | 18:14

The P/E ratio of Tatva Chintan Pharma Chem is 75.8 As on 22 July, 2026 | 18:14

The PB ratio of Tatva Chintan Pharma Chem is 5 As on 22 July, 2026 | 18:14

The 52 week High & Low of Tatva Chintan Pharma Chem is ₹1785/₹976.4 respectively As on 22 July, 2026 | 18:14

Open FREE Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23